Study summary
Acalabrutinib kept most people in response for more than 5 years
94.6%response rate in relapsed disease
What was tested
Acalabrutinib, a daily BTK inhibitor pill, for treatment-naive and relapsed Waldenström macroglobulinemia.
What they found
- Response rates were 92.9% in untreated and 94.6% in relapsed patients.
- Estimated 66-month progression-free survival was 83.6% (untreated) and 52.0% (relapsed).
- Heart events of interest occurred in 20.8%.
What it means
Confirms that continuous BTK inhibitor treatment gives long-lasting control.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.